上海医药集团股份有限公司(简称“上海医药”,601607.SH;02607.HK)近日发布的2025年第一季度财报显示,创新药业务实现销售收入125亿元,同比增长23.2%。此前发布的年报数据显示,公司2024年医药商业创新药板块实现销售收入305亿元,同比增幅为29.7%。 公开资料显示,作为沪港两地上市的大型医药产业集团,上海医药主营业务覆盖医药工业与商业,2024年营业收入2752.51...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.